Entera Bio Ltd.
ENTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.81 | 0.04 | -0.04 | 0.05 |
| FCF Yield | 5.55% | -1.87% | -1.91% | -1.84% |
| EV / EBITDA | 0.00 | -29.44 | -23.99 | -30.71 |
| Quality | ||||
| ROIC | 0.00% | -14.65% | 12.72% | -28.04% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.62 | 0.55 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | 106.90% | 96.14% | 50.06% | 10.54% |
| Free Cash Flow Growth | 402.23% | -17.56% | 3.95% | 31.75% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 4.00 | 4.83 | 3.61 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -333.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -4,924.29 | -17.14 | -6.59 |